ES2507496T3 - Polipéptido para tratar o evitar adherencias - Google Patents

Polipéptido para tratar o evitar adherencias Download PDF

Info

Publication number
ES2507496T3
ES2507496T3 ES09830789.5T ES09830789T ES2507496T3 ES 2507496 T3 ES2507496 T3 ES 2507496T3 ES 09830789 T ES09830789 T ES 09830789T ES 2507496 T3 ES2507496 T3 ES 2507496T3
Authority
ES
Spain
Prior art keywords
adhesions
polypeptide
adhesion
composition
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09830789.5T
Other languages
English (en)
Spanish (es)
Inventor
Alyssa Panitch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Application granted granted Critical
Publication of ES2507496T3 publication Critical patent/ES2507496T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
ES09830789.5T 2008-10-20 2009-10-20 Polipéptido para tratar o evitar adherencias Active ES2507496T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10683408P 2008-10-20 2008-10-20
US106834P 2008-10-20
PCT/US2009/061345 WO2010065206A1 (en) 2008-10-20 2009-10-20 Polypeptide for treating or preventing adhesions

Publications (1)

Publication Number Publication Date
ES2507496T3 true ES2507496T3 (es) 2014-10-15

Family

ID=42108870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09830789.5T Active ES2507496T3 (es) 2008-10-20 2009-10-20 Polipéptido para tratar o evitar adherencias

Country Status (11)

Country Link
US (1) US9034815B2 (enExample)
EP (1) EP2349310B1 (enExample)
JP (1) JP5785085B2 (enExample)
KR (2) KR20170001756A (enExample)
CN (1) CN102256613B (enExample)
AU (1) AU2009322865B2 (enExample)
BR (1) BRPI0919759A2 (enExample)
CA (1) CA2741302C (enExample)
DK (1) DK2349310T3 (enExample)
ES (1) ES2507496T3 (enExample)
WO (1) WO2010065206A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2155228T3 (da) 2007-01-10 2014-07-07 Purdue Research Foundation Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
AU2009324661A1 (en) 2008-12-10 2011-07-07 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
SG194135A1 (en) 2011-04-12 2013-11-29 Matrix Inc Moerae Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR102266659B1 (ko) 2012-03-23 2021-06-17 아미크로베, 인코포레이티드. 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2016061145A1 (en) * 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
KR20170083063A (ko) * 2014-11-17 2017-07-17 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
US10087225B2 (en) * 2015-01-08 2018-10-02 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
RU2017135072A (ru) 2015-03-12 2019-04-10 Мори Матрикс, Инк. Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
AU2018249552A1 (en) 2017-04-06 2019-10-31 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
RU2741247C1 (ru) * 2020-10-13 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики перитонеальных спаек женского таза

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NL192564C (nl) 1982-10-08 1997-10-03 Glaxo Group Ltd Inrichting voor het toedienen van medicamenten aan patiënten.
EP0211595B1 (en) 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CN1048254C (zh) 1993-12-09 2000-01-12 托马斯杰弗逊大学 用于将预定的改变引入靶基因中的化合物
WO2003084481A2 (en) 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
EP1824336A4 (en) * 2004-12-02 2009-10-14 Univ North Carolina INHIBITION OF PHOSPHORYLATION HSP27 TO TREAT VESICATION DISORDERS
EP1868629B1 (en) * 2005-04-15 2014-10-22 Arizona Biomedical Research Commission Therapeutic fusion peptides for the treatment of metastatic cancer
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
DK2155228T3 (da) * 2007-01-10 2014-07-07 Purdue Research Foundation Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
WO2008109794A2 (en) * 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
WO2009123759A2 (en) * 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions

Also Published As

Publication number Publication date
KR20110095867A (ko) 2011-08-25
KR20170001756A (ko) 2017-01-04
WO2010065206A1 (en) 2010-06-10
JP2012506442A (ja) 2012-03-15
CN102256613B (zh) 2014-09-10
CA2741302C (en) 2017-02-28
DK2349310T3 (da) 2014-08-11
EP2349310A1 (en) 2011-08-03
KR101884616B1 (ko) 2018-08-06
US20100098760A1 (en) 2010-04-22
EP2349310B1 (en) 2014-07-23
AU2009322865B2 (en) 2013-07-18
US20130101671A9 (en) 2013-04-25
CN102256613A (zh) 2011-11-23
AU2009322865A1 (en) 2010-06-10
BRPI0919759A2 (pt) 2017-03-21
US9034815B2 (en) 2015-05-19
JP5785085B2 (ja) 2015-09-24
CA2741302A1 (en) 2010-06-10
EP2349310A4 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
AU2009322865B2 (en) Polypeptide for treating or preventing adhesions
ES2594281T3 (es) Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
JP2010155842A5 (enExample)
ES2794082T3 (es) Uso de dímeros de IL-22 en la fabricación de medicamentos para tratar la pancreatitis
JP2012528191A (ja) Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
ES2373039T3 (es) Composiciones y métodos para el tratamiento de lesiones del cns.
WO2011149964A2 (en) Methods for treating or preventing vascular graft failure
AU2004277954A1 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
ES2218666T3 (es) Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2).
ES2297286T3 (es) Uso de productos proteicos del factor de crecimiento de queratinocitos-2.
WO2019129314A1 (es) Péptido antagonista de la actividad de la interleucina-15
ES2360610T3 (es) Tratamiento de la insuficiencia renal aguda con trombomodulina soluble.
HK1161105B (en) Polypeptide for treating or preventing adhesions
HK1161105A (en) Polypeptide for treating or preventing adhesions
ES2351005B1 (es) Uso de anhidrasa carbónica ii para la elaboración de un medicamento.
JP2000509073A (ja) 虚血再灌流傷害の治療または予防の方法
JP2023511245A (ja) Ｖｅ－ｐｔｐホスファターゼの阻害は腎臓を虚血再灌流障害から保護する
ES2799829T3 (es) Proteínas de fusión recombinantes para la prevención o el tratamiento de adherencias en tejidos u órganos
WO2012030949A2 (en) B2-glycoprotein i peptide inhibitors
WO2010006635A1 (en) Treatment of inflammatory bowel disease
CN106061495B (zh) 肺内炎症的减弱
MX2014010209A (es) Agente inhibidor para acumulacion de fluido de la cavidad corporal.
CA2738757A1 (en) Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury
CN118369351A (zh) Dsg2组合物和方法
CN1223587A (zh) 治疗或预防局部缺血－再灌注损伤的方法